<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01793298</url>
  </required_header>
  <id_info>
    <org_study_id>ASM-024/I-II/STA-03</org_study_id>
    <nct_id>NCT01793298</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of ASM-024 Administered to Healthy Subjects and Subjects With Moderate Asthma</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of ASM-024 Administered by Dry Powder Inhalation to Healthy Subjects and Subjects With Stable Moderate Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asmacure Ltée</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asmacure Ltée</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of the dry powder&#xD;
      formulation of ASM-024 following single and multiple administration by inhalation of&#xD;
      ascending doses in healthy subjects and subjects with stable moderate asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II, randomized, double-blind, placebo-controlled study of single ascending&#xD;
      and multiple ascending doses of ASM-024 administered by dry powder inhalation to healthy&#xD;
      subjects and subjects with stable moderate asthma. The goal of this study is to evaluate the&#xD;
      safety, tolerability and pharmacokinetic profile of a new, dry powder formulation of ASM-024.&#xD;
      The doses that will be tested in subjects with asthma will be determined based on the&#xD;
      information collected first in healthy volunteers. In addition to standard safety and&#xD;
      tolerability evaluations, the acute effects of the study medication on the airways will be&#xD;
      assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy&#xD;
  </why_stopped>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events, spirometry</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects - ASM-024 Single Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of ascending doses of ASM-024</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Subjects - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single administration of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Subjects - ASM-024 Repeat Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat administration of ascending doses of ASM-024</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Subjects - Placebo Repeat Administration</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Repeat administration of ascending doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with Asthma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeat administration of ascending doses of ASM-024 or placebo in a crossover fashion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASM-024</intervention_name>
    <description>Ascending doses of ASM-024</description>
    <arm_group_label>Healthy Subjects - ASM-024 Repeat Administration</arm_group_label>
    <arm_group_label>Healthy Subjects - ASM-024 Single Administration</arm_group_label>
    <arm_group_label>Subjects with Asthma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy Volunteers:&#xD;
&#xD;
          -  Healthy male or female adult, 18 to 55 years of age ; non-smoker or former smoker;&#xD;
&#xD;
          -  Normal lung function; and&#xD;
&#xD;
          -  Normal 12-lead ECG&#xD;
&#xD;
        Asthmatics:&#xD;
&#xD;
          -  Male or female adult, 18 to 60 years of age with diagnosis of moderate asthma&#xD;
             according to the GINA Guidelines and on regular inhaled corticosteroids with or&#xD;
             without short or long-acting beta 2-agonists;&#xD;
&#xD;
          -  Non-smoker or former smoker;&#xD;
&#xD;
          -  FEV1 ≥ 70 % predicted in the absence of medications for asthma;&#xD;
&#xD;
          -  Baseline methacholine PC20 ≤ 16 mg/mL; and&#xD;
&#xD;
          -  Normal 12-lead ECG.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Healthy Volunteers:&#xD;
&#xD;
          -  Clinically significant illness or surgery within 8 weeks prior to first administration&#xD;
             of the study medication;&#xD;
&#xD;
          -  Significant medical history that, in the Investigator's opinion, may adversely affect&#xD;
             participation;&#xD;
&#xD;
          -  History of allergy or significant adverse reaction to drugs similar to ASM-024, to&#xD;
             nicotine, or to cholinergic drugs or any drugs with a similar chemical structure;&#xD;
&#xD;
          -  History of hypersensitivity (anaphylaxis, angioedema) to any drug;&#xD;
&#xD;
          -  Use of any drug known to induce or inhibit hepatic drug metabolism, within 30 days&#xD;
             prior to first administration of the study medication;&#xD;
&#xD;
          -  Positive pregnancy test for female subjects;&#xD;
&#xD;
          -  Use of medications known to prolong QT/QTc interval within 14 days prior to the first&#xD;
             administration of the study medication;&#xD;
&#xD;
          -  Clinically significant 12 lead ECG abnormalities at Screening;;&#xD;
&#xD;
          -  Clinically significant physical examination or laboratory findings at Screening;&#xD;
&#xD;
          -  History of alcohol or drug abuse;&#xD;
&#xD;
          -  Tobacco use within 12 months prior to Screening, or nicotine-containing products&#xD;
             within 6 months prior to Screening. History of smoking must be ≤ 10 pack-years;&#xD;
&#xD;
          -  Positive hepatitis B or C or HIV test at Screening;&#xD;
&#xD;
          -  Investigational drug within 30 days prior to first administration of the study&#xD;
             medication, or long-acting investigational drug within 90 days prior to first&#xD;
             administration of the study medication;&#xD;
&#xD;
          -  Previous exposure to ASM-024; and&#xD;
&#xD;
          -  Women of child-bearing potential and male participants unwilling or unable to use&#xD;
             accepted methods of birth control.&#xD;
&#xD;
        Asthmatics:&#xD;
&#xD;
          -  Clinically significant illness or surgery within 8 weeks prior to first administration&#xD;
             of the study medication;&#xD;
&#xD;
          -  Significant medical history that, in the Investigator's opinion, may adversely affect&#xD;
             participation;&#xD;
&#xD;
          -  History of allergy or significant adverse reaction to drugs similar to ASM-024, to&#xD;
             nicotine, or to cholinergic drugs or any drugs with a similar chemical structure;&#xD;
&#xD;
          -  History of hypersensitivity (anaphylaxis, angioedema) to any drug;&#xD;
&#xD;
          -  Use of any drug known to induce or inhibit hepatic drug metabolism, within 30 days&#xD;
             prior to first administration of the study medication;&#xD;
&#xD;
          -  Positive pregnancy test for female subjects;&#xD;
&#xD;
          -  Use of medications known to prolong QT/QTc interval;&#xD;
&#xD;
          -  Clinically significant 12 lead ECG at Screening;&#xD;
&#xD;
          -  Clinically significant physical examination or laboratory findings or abnormal vital&#xD;
             signs;&#xD;
&#xD;
          -  Baseline methacholine PC20 &gt; 16 mg/mL at Screening;&#xD;
&#xD;
          -  History of illicit drug use or alcohol abuse within 12 months of Screening;&#xD;
&#xD;
          -  Tobacco use within 12 months prior to Screening, or nicotine-containing products&#xD;
             within 6 months prior to Screening. History of smoking must be ≤ 10 pack-years;&#xD;
&#xD;
          -  Positive hepatitis B or C or HIV test at Screening;&#xD;
&#xD;
          -  Any of the following concomitant medications preceding the administration of&#xD;
             methacholine during Screening and preceding the administration of the study medication&#xD;
             at Visit 1: (i) oral or i.v. corticosteroids within 1 month; (ii) inhaled or&#xD;
             intranasal corticosteroids within 48 hours; (iii) long-acting beta-2-agonists within&#xD;
             48 hours; (iv) short-acting beta-2-agonists within 8 hours; (v) anticholinergic&#xD;
             aerosol within 24 hours; (vi) theophyline-containing products within 48 hours; (vii)&#xD;
             NSAIDs within 7 days preceding the administration of methacholine during Screening and&#xD;
             throughout the study; and (viii) antihistaminic drugs within 3 days;&#xD;
&#xD;
          -  Investigational drug within 30 days of Screening; long-acting investigational drug&#xD;
             within 90 days of Screening;&#xD;
&#xD;
          -  Previous exposure to ASM-024; and&#xD;
&#xD;
          -  Women of child-bearing potential and male participants unwilling or unable to use&#xD;
             accepted methods of birth control.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvon Cormier, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Asmacure Ltée</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PharmaNet</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1P 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>February 14, 2013</study_first_submitted>
  <study_first_submitted_qc>February 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

